1
|
Falion RI, Beketova YI, Pospishil YO. COMPREHENSIVE STUDY OF MANIFESTATIONS OF BRAIN TISSUE RESOLUTION IN CASE OF VARIOUS TYPES OF STROKE. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 2022; 75:791-797. [PMID: 35633349 DOI: 10.36740/wlek202204108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
OBJECTIVE The aim: The study is to research the resolution of perifocal brain tissue at various type strokes using immunomorphology. PATIENTS AND METHODS Materials and methods: The immunohistochemical study of perifocal brain tissue in 21 cases of various strokes types was condacted. RESULTS Results: When comparing the GFAP + astrocytes detection area at IS, HS and IS with HT, no significant difference was found. At the 1st degree of GFAP + astrocytes were in the border around the necrosis nucleus at IS and IS with HT, and at HS GFAP + astrocytes accumulated along the hematoma edge. CD34 + cells were found in most cases of strokes. Over time, cases with a larger CD34 + cells detection area increased (Kendal's Tau = 0.512, p = 0.001) in all groups. The capillary network at HS was around the hematoma and formed a gliomesodermal capsule with microglia and inflammation. 1st degree τ-protein accumulation was detected in 2/3 of cases (66.7%) of all strokes without significant difference. If compared in different stroke periods, -protein detection frequency increased and accumulated in brain structures - Kendal's Tau = 0.359; p = 0.023. CONCLUSION Conclusions: With the development of the disease, the number of cases with a larger area of detection of GFAP + astrocytes and CD34 + cells increased in strokes of various types. τ-protein was detected in neurons in all variants of ACVA in the first period.
Collapse
Affiliation(s)
| | - Yuliya I Beketova
- SHUPYK NATIONAL MEDICAL ACADEMY OF POSTGRADUATE EDUCATION, KYIV, UKRAINE
| | | |
Collapse
|
2
|
Role of stem cell mobilization in the treatment of ischemic diseases. Arch Pharm Res 2019; 42:224-231. [PMID: 30680545 DOI: 10.1007/s12272-019-01123-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Accepted: 01/16/2019] [Indexed: 12/13/2022]
Abstract
Stem cell mobilization plays important roles in the treatment of severe ischemic diseases, including myocardial infarction, limb ischemia, ischemic stroke, and acute kidney injury. Stem cell mobilization refers to the egress of heterogeneous stem cells residing in the bone marrow into the peripheral blood. In the clinic, granulocyte colony-stimulating factor (G-CSF) is the drug most commonly used to induce stem cell mobilization. Plerixafor, a direct antagonist of CXCR4, is also frequently used alone or in combination with G-CSF to mobilize stem cells. The molecular mechanisms by which G-CSF induces stem cell mobilization are well characterized. Briefly, G-CSF activates neutrophils in the bone marrow, which then release proteolytic enzymes, such as neutrophil elastase, cathepsin G, and matrix metalloproteinase 9, which cleave a variety of molecules responsible for stem cell retention in the bone marrow, including CXCL12, VCAM-1, and SCF. Subsequently, stem cells are released from the bone marrow into the peripheral blood. The released stem cells can be collected and used in autologous or allogeneic transplantation. To identify better conditions for stem cell mobilization in the treatment of acute and chronic ischemic diseases, several preclinical and clinical studies have been conducted over the past decade on various mobilizing agents. In this paper, we are going to review methods that induce mobilization of stem cells from the bone marrow and introduce the application of stem cell mobilization to therapy of ischemic diseases.
Collapse
|
3
|
A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement. ARCHIVES OF NEUROSCIENCE 2018. [DOI: 10.5812/archneurosci.59387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Abstract
Acupuncture is potentially beneficial for post-stroke rehabilitation and is considered a promising preventive strategy for stroke. Electroacupuncture pretreatment or treatment after ischemic stroke by using appropriate electroacupuncture parameters generates neuroprotective and neuroregenerative effects that increase cerebral blood flow, regulate oxidative stress, attenuate glutamate excitotoxicity, maintain blood-brain barrier integrity, inhibit apoptosis, increase growth factor production, and induce cerebral ischemic tolerance.
Collapse
Affiliation(s)
- Qwang-Yuen Chang
- Department of Family Medicine, Lin Shin Hospital, Taichung, Taiwan, China
| | - Yi-Wen Lin
- Research Center for Chinese Medicine and Acupuncture; Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan, China
| | - Ching-Liang Hsieh
- Research Center for Chinese Medicine and Acupuncture; Graduate Institute of Acupuncture Science, College of Chinese Medicine; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University; Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan, China
| |
Collapse
|
5
|
Shi W, Wei X, Wang Z, Han H, Fu Y, Liu J, Zhang Y, Guo J, Dong C, Zhou D, Zhou Q, Chen Y, Yi F. HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injury. J Cell Mol Med 2016; 20:1139-49. [PMID: 26865248 PMCID: PMC4882992 DOI: 10.1111/jcmm.12803] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Accepted: 12/22/2015] [Indexed: 01/08/2023] Open
Abstract
Histone deacetylase (HDAC) 9, a member of class II HDACs, regulates a wide variety of normal and abnormal physiological functions, which is usually expressed at high levels in the brain and skeletal muscle. Although studies have highlighted the importance of HDAC-mediated epigenetic processes in the development of ischaemic stroke and very recent genome-wide association studies have identified a variant in HDAC9 associated with large-vessel ischemic stroke, the molecular events by which HDAC9 induces cerebral injury keep unclear. In this study, we found that HDAC9 was up-regulated in the ischaemic cerebral hemisphere after cerebral ischaemia/reperfusion (I/R) injury in rats and in vivo gene silencing of HDAC9 by recombinated lentivirus infection in the brain reduced cerebral injury in experimental stroke. We further demonstrated that HDAC9 contributed to oxygen-glucose deprivation-induced brain microvessel endothelial cell dysfunction as demonstrated by the increased inflammatory responses, cellular apoptosis and endothelial cell permeability dysfunction accompanied by reduced expression of tight-junction proteins. We further found that HDAC9 suppressed autophagy, which was associated with endothelial dysfunction. This study for the first time provides direct evidence that HDAC9 contributes to endothelial cell injury and demonstrates that HDAC9 is one of critical components of a signal transduction pathway that links cerebral injury to epigenetic modification in the brain.
Collapse
Affiliation(s)
- Weichen Shi
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China.,Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Xinbing Wei
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Ziying Wang
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Huirong Han
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Yi Fu
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Jiang Liu
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Yan Zhang
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Jian Guo
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Chuanqiao Dong
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Di Zhou
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Quan Zhou
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| | - Yuxin Chen
- Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Fan Yi
- Department of Pharmacology, Shandong University School of Medicine, Jinan, China
| |
Collapse
|
6
|
Costa R, Bergwerf I, Santermans E, De Vocht N, Praet J, Daans J, Le Blon D, Hoornaert C, Reekmans K, Hens N, Goossens H, Berneman Z, Parolini O, Alviano F, Ponsaerts P. Distinct In Vitro Properties of Embryonic and Extraembryonic Fibroblast-Like Cells are Reflected in their in Vivo Behavior following Grafting in the Adult Mouse Brain. Cell Transplant 2015; 24:223-33. [DOI: 10.3727/096368913x676196] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Although intracerebral transplantation of various fibroblast(-like) cell populations has been shown feasible, little is known about the actual in vivo remodeling of these cellular grafts and their environment. In this study, we aimed to compare the in vitro and in vivo behavior of two phenotypically similar—but developmentally distinct—fibroblast-like cell populations, namely, mouse embryonic fibroblasts (mEFs) and mouse fetal membrane-derived stromal cells (mFMSCs). While both mEFs and mFMSCs are readily able to reduce TNF-α secretion by LPS/IFN-γ-activated BV-2 microglia, mFMSCs and mEFs display strikingly opposite behavior with regard to VEGF production under normal and inflammatory conditions. Whereas mFMSCs downregulate VEGF production upon coculture with LPS/IFN-γ-activated BV-2 microglia, mEFs upregulate VEGF production in the presence of LPS/IFN-γ-activated BV-2 microglia. Subsequently, in vivo grafting of mFMSCs and mEFs revealed no difference in microglial and astroglial responses toward the cellular grafts. However, mFMSC grafts displayed a lower degree of neoangiogenesis compared to mEF grafts, thereby potentially explaining the lower cell number able to survive in mFMSC grafts. In summary, our results suggest that physiological differences between fibroblast-like cell populations might lie at the basis of variations in histopathological and/or clinical outcome following cell grafting in mouse brain.
Collapse
Affiliation(s)
- Roberta Costa
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - Irene Bergwerf
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Eva Santermans
- Center for Statistics, I-Biostat, Hasselt University, Hasselt, Belgium
| | - Nathalie De Vocht
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Jelle Praet
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Jasmijn Daans
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Debbie Le Blon
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Chloé Hoornaert
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Kristien Reekmans
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Niel Hens
- Center for Statistics, I-Biostat, Hasselt University, Hasselt, Belgium
- Centre for Health Economic Research and Modeling Infectious Diseases (Chermid), University of Antwerp, Antwerp, Belgium
| | - Herman Goossens
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Zwi Berneman
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| | - Ornella Parolini
- Centro di Ricerca E. Menni, Fondazione Poliambulanza - Istituto Ospedaliero, Brescia, Italy
| | - Francesco Alviano
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - Peter Ponsaerts
- Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium
- Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium
| |
Collapse
|
7
|
Advancing critical care medicine with stem cell therapy and hypothermia for cerebral palsy. Neuroreport 2014; 24:1067-71. [PMID: 24169604 DOI: 10.1097/wnr.0000000000000062] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
With limited clinical trials on stem cell therapy for adult stroke underway, the assessment of efficacy also needs to be considered for neonatal hypoxic-ischemic brain injury, considering its distinct symptoms. The critical nature of this condition leads to establishment of deficits that last a lifetime. Here, we will highlight the progress of current translational research, commenting on the critical nature of the disease, stem cell sources, the use of hypothermia, safety and efficacy of each treatment, modes of action, and the possibility of combination therapy. With this in mind, we reference translational guidelines established by a consortium of research partners called Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS). The guidelines of STEPS are directed toward evaluating outcomes of cell therapy in adult stroke; however, we identify the overlapping pathology, as we believe that these guidelines will serve well in the investigation of neonatal hypoxic-ischemic therapy. Finally, we discuss emerging treatments and a case report, altogether suggesting that the potential for these treatments to be used in synergy has arrived and the time for advancing stem cell use in combination with hypothermia for cerebral palsy is now.
Collapse
|
8
|
Li J, Zhu H, Chen Y, Deng W, Li Q, Lu S, Xu Y, Huang L, Ma C, Zhao C, Wang R, Qin C. The distribution of transplanted human mesenchymal stem cells in the CNS of young Macaca fascicularis. Brain Res 2014; 1579:1-9. [PMID: 25050543 DOI: 10.1016/j.brainres.2014.07.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 07/10/2014] [Accepted: 07/11/2014] [Indexed: 01/10/2023]
Abstract
Mesenchymal stem cell (MSC)-based therapies have generated much hope and promise as a potential source of cells for cell-based therapeutic strategies in pediatric degenerative diseases. However, the distribution and migratory routes of MSCs are unknown. Here, real-time PCR and microscopy were used to observe the migration and distribution of labeled human MSCs (hMSCs) transplanted into the striatum of young Macaca fascicularis. Moreover, the differentiation of hMSCs was also detected using immunofluorescence. We found that hMSCs were mainly located near the injection site in the brain and in the anterior brain after 2 weeks. After 4 weeks, the hMSCs had dispersed and could be detected in each brain slice and were more uniformly distributed than after 2 weeks. The hMSCs showed a preference for migration towards blood vessels, which may be one of the migratory routes used by hMSCs. Additionally, hMSCs could be observed to give rise to NeuN- and GFAP-positive cells. Transplanted hMSCs also increased the expression levels of N-cadherin in the host brain tissue, which may be one factor that drives the migration and differentiation of hMSCs after transplantation. These results provide preclinical evidence that MSC-based therapies may represent an efficacious alternative to more conventional treatment regimens for a variety of pediatric neurologic disorders.
Collapse
Affiliation(s)
- Jiamei Li
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China; Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
| | - Hua Zhu
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Yunxin Chen
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Wei Deng
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Qin Li
- Motac Collaborative Laboratory, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Shan Lu
- Institute of Basic Medical Sciences and School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
| | - Yanfeng Xu
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Lan Huang
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Chunmei Ma
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China
| | - Chunhua Zhao
- Institute of Basic Medical Sciences and School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
| | - Renzhi Wang
- Peking Union Medical College Hospital, Beijing 100730, China
| | - Chuan Qin
- Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Beijing 100005, China.
| |
Collapse
|
9
|
Achyut BR, Varma NRS, Arbab AS. Application of Umbilical Cord Blood Derived Stem Cells in Diseases of the Nervous System. ACTA ACUST UNITED AC 2014; 4. [PMID: 25599002 DOI: 10.4172/2157-7633.1000202] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Umbilical cord blood (UCB) derived multipotent stem cells are capable of giving rise hematopoietic, epithelial, endothelial and neural progenitor cells. Thus suggested to significantly improve graft-versus-host disease and represent the distinctive therapeutic option for several malignant and non-malignant diseases. Recent advances in strategies to isolate, expand and shorten the timing of UCB stem cells engraftment have tremendously improved the efficacy of transplantations. Nervous system has limited regenerative potential in disease conditions such as cancer, neurodegeneration, stroke, and several neural injuries. This review focuses on application of UCB derived stem/progenitor cells in aforementioned pathological conditions. We have discussed the possible attempts to make use of UCB therapies to generate neural cells and tissues with developmental and functional similarities to neuronal cells. In addition, emerging applications of UCB derived AC133+ (CD133+) endothelial progenitor cells (EPCs) as imaging probe, regenerative agent, and gene delivery vehicle are mentioned that will further improve the understanding of use of UCB cells in therapeutic modalities. However, safe and effective protocols for cell transplantations are still required for therapeutic efficacy.
Collapse
Affiliation(s)
- Bhagelu R Achyut
- Tumor Angiogenesis Lab, Cancer Center, Georgia Regents University, Augusta, GA 30912, USA
| | | | - Ali S Arbab
- Tumor Angiogenesis Lab, Cancer Center, Georgia Regents University, Augusta, GA 30912, USA
| |
Collapse
|